Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Head & Neck Cancer Therapeutics Market

Head & Neck Cancer Therapeutics Market Share

Report ID: GMI11024
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Head & Neck Cancer Therapeutics Market Share

The competitive landscape in the market is dynamic and highly competitive, driven by both established pharmaceutical giants and innovative biotechnology firms. Major players, such as Elli Lilly and Company, Sanofi dominate the market due to their strong brand presence and focus on developing novel immunotherapies and targeted therapies, which have become the standard of care in treating head and neck cancers. Their leadership is supported by successful clinical trials, regulatory approvals, and strong marketing strategies.

Head & Neck Cancer Therapeutics Market Companies

Prominent players operating in the head & neck cancer therapeutics industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company (BMS)
C.H. Boehringer Sohn AG & Co. KG
Clinigen Group plc.
Coherus BioSciences
Cumberland Pharmaceuticals, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GSK plc
Merck & Co., Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The head & neck cancer therapeutics industry size was valued at USD 1.8 billion in 2023 and is set to register 8.9% CAGR from 2024 to 2032 primarily driven by the increasing prevalence of head and neck cancer.

The immunotherapy segment recorded USD 972.7 million in 2023, led by ongoing development of new formulations

The injectable route of administration segment recorded 57.4% share of the head & neck cancer therapeutics industry in 2023 as these drugs target specific proteins on cancer cells or immune cells,

North America head & neck cancer therapeutics industry size is anticipated to reach USD 1.4 billion by 2032 led by the presence of robust healthcare system and established regulatory pathways